Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MTAU9937A in moderate Alzheimer's disease
2018-003398-87Phase 2Active
- Sponsor
- Roche
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing MTAU9937A with Placebo (2 arms). Primary endpoint: Change from baseline to Week 49 in cognitive function. Started May 2019; status: active.
02
Drugs
semorinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2018-003398-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003398-87.